William Blair Investment Management LLC cut its holdings in Glaukos Corporation (NYSE:GKOS – Free Report) by 1.5% in the third quarter, Holdings Channel reports. The fund owned 651,456 shares of the medical instruments supplier’s stock after selling 10,219 shares during the quarter. William Blair Investment Management LLC’s holdings in Glaukos were worth $106,963,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Quantinno Capital Management LP increased its position in Glaukos by 964.0% during the 1st quarter. Quantinno Capital Management LP now owns 30,836 shares of the medical instruments supplier’s stock valued at $3,320,000 after purchasing an additional 27,938 shares during the period. TimesSquare Capital Management LLC bought a new stake in shares of Glaukos in the 2nd quarter valued at about $20,293,000. BlackRock Inc. bought a new stake in shares of Glaukos in the 2nd quarter valued at about $1,333,318,000. Susquehanna Fundamental Investments LLC bought a new stake in shares of Glaukos in the 2nd quarter valued at about $3,361,000. Finally, Wellington Management Group LLP lifted its position in shares of Glaukos by 187.1% in the 2nd quarter. Wellington Management Group LLP now owns 428,215 shares of the medical instruments supplier’s stock worth $59,847,000 after purchasing an additional 279,065 shares during the period. 99.04% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
GKOS has been the topic of a number of recent research reports. Citigroup increased their price objective on shares of Glaukos from $225.00 to $247.00 and gave the company a “buy” rating in a research note on Thursday, October 29th. Zacks Research raised shares of Glaukos from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 28th. Wells Fargo & Company boosted their price objective on shares of Glaukos from $178.00 to $226.00 and gave the stock an “overweight” rating in a research note on Thursday, October 29th. Stifel Nicolaus upped their target price on Glaukos from $190.00 to $225.00 and gave the stock a “buy” rating in a report on Thursday, October 29th. Finally, HC Wainwright upped their target price on Glaukos from $195.00 to $248.00 and gave the stock a “buy” rating in a report on Thursday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Glaukos currently has an average rating of “Moderate Buy” and a consensus price target of $218.00.
Check Out Our Latest Report on Glaukos
Insider Activity
In related news, Director Gilbert Kliman sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $253.00, for a total transaction of $632,500.00. Following the completion of the transaction, the director owned 37,406 shares in the company, valued at $9,463,718. The trade was a 6.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 5.90% of the stock is currently owned by insiders.
Glaukos Price Performance
GKOS opened at $245.60 on Monday. The firm has a market capitalization of $14.54 billion, a PE ratio of -83.54 and a beta of 0.68. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.57 and a quick ratio of 4.09. The business’s 50-day moving average is $184.61 and its two-hundred day moving average is $147.10. Glaukos Corporation has a 1 year low of $87.32 and a 1 year high of $255.18.
Glaukos (NYSE:GKOS – Get Free Report) last released its quarterly earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 EPS for the quarter, beating the consensus estimate of ($0.10) by $0.57. Glaukos had a negative net margin of 24.60% and a negative return on equity of 0.97%. The business had revenue of $211.03 million during the quarter, compared to analyst estimates of $168.04 million. During the same period in the prior year, the firm posted ($0.16) earnings per share. The company’s quarterly revenue was up 58.0% on a year-over-year basis. Research analysts anticipate that Glaukos Corporation will post 0.50 earnings per share for the current fiscal year.
Glaukos Profile
Glaukos Corporation is an ophthalmic medical technology company that develops and commercializes treatments for glaucoma and other eye disorders. Its portfolio includes minimally invasive glaucoma surgery (MIGS) devices, such as the iStent family, and iDose TR, an implant designed to deliver glaucoma medication inside the eye over an extended period. The company also offers products for corneal disorders, including technology used in corneal cross-linking procedures to treat keratoconus and other conditions that weaken the cornea.
Further Reading
- Five stocks we like better than Glaukos
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS – Free Report).
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.
